Proteomic Biomarkers for Primary Open Angle Glaucoma

原发性开角型青光眼的蛋白质组生物标志物

基本信息

批准号：
7684131
负责人：
JOHN W CRABB
金额：
$ 19.63万
依托单位：
CLEVELAND CLINIC LERNER COM-CWRU
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-15 至 2011-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7684131
关键词：
Affect American Biological Markers Blindness Blood Blood Tests Cardiovascular Diseases Case-Control Studies Cholesterol Clinical Clinical Medicine Control Groups Detection Development Diagnostic Disease Disease Progression Early Diagnosis Elderly Enzyme-Linked Immunosorbent Assay Experimental Designs Glaucoma Goals Human Individual Intervention Lead Literature MALDI-TOF Mass Spectrometry Mass Spectrum Analysis Measurement Measures Methods Modification Monitor Ocular Hypertension Optic Nerve Pathogenesis Pathologic Pathology Patients Pattern Peptides Phase Physicians Pilot Projects Plasma Plasma Proteins Population Post-Translational Protein Processing Predisposition Preventive Primary Open Angle Glaucoma Proteins Proteolysis Proteomics Public Health Relative (related person)Research Resolution Risk Risk Management Serum Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Staging Technology Testing Tissues Trabecular meshwork structure Treatment Efficacy United States adduct argpyrimidine base case control innovation insight prevent prognostic protein aminoacid sequence public health relevance tandem mass spectrometry

项目摘要

DESCRIPTION (provided by applicant): Primary open angle glaucoma (POAG) is one of the leading causes of blindness in the elderly population worldwide. Slowing or preventing the progression of this disease is an urgent public health goal. We hypothesize that biomarkers exist in the blood of individuals susceptible to developing POAG that will allow identification of those at risk prior to clinical evidence of the disease. A case-control pilot study is proposed to test the hypothesis that plasma contains diagnostic biomarkers for POAG. Plasma will be collected from clinically documented patients from the United States in four study groups, including a control group and three POAG groups (ocular hypertension, possible POAG and definite POAG). ELISA will be used to screen plasma for protein oxidative modifications that may serve as POAG plasma biomarkers. High resolution MALDI TOF TOF and QTOF mass spectrometry will be used to screen plasma for proteomic patterns and/or to determine the sequence of POAG diagnostic plasma peptides. The long term goal is the development of routine diagnostic technology for use in clinical medicine to predict POAG susceptibility and to monitor therapeutic efficacy, essentially as serum cholesterol measurements are used today for risk management for cardiovascular disease. This research will lead to methods for early detection of "POAG at risk" individuals, new methods for measuring POAG therapeutic efficacies and new insights into mechanisms of glaucoma pathology. PUBLIC HEALTH RELEVANCE: Primary open angle glaucoma (POAG) is the most common form of glaucoma and affects about 3 million Americans and over 70 million people worldwide. Slowing or preventing the progression of this disease is an urgent public health goal. The proposed research will lead to methods for early detection of "POAG at risk" individuals, new methods for measuring POAG therapeutic efficacies and new insights into the mechanisms of glaucoma pathology.

描述（由申请人提供）：主要的开角绿色素瘤（POAG）是全球老年人口失明的主要原因之一。放缓或阻止这种疾病的进展是一个紧迫的公共卫生目标。我们假设生物标志物存在于容易发展POAG的个体的血液中，这些POAG将允许在疾病的临床证据之前识别有风险的人。提出了一项病例对照试验研究，以检验血浆中包含POAG诊断生物标志物的假设。血浆将从四个研究组的美国临床记录的患者中收集，包括对照组和三个POAG组（眼高血压，可能的POAG和确定的POAG）。 ELISA将用于筛选血浆，以进行蛋白质氧化修饰，这些修饰可以用作POAG血浆生物标志物。高分辨率MALDI TOF TOF和QTOF质谱法将用于筛选等离子体的蛋白质组学模式和/或确定POAG诊断等离子体肽的序列。长期目标是开发常规诊断技术，用于预测POAG易感性和监测治疗功效，从本质上讲，当今血清胆固醇测量值用于心血管疾病的风险管理。这项研究将导致早期发现“处于风险的POAG”个体的方法，测量POAG治疗效率的新方法以及对青光眼病理学机制的新见解。公共卫生相关性：主要的开角青光眼（POAG）是青光眼最常见的形式，影响了大约300万美国人，全球超过7000万人。放缓或阻止这种疾病的进展是一个紧迫的公共卫生目标。拟议的研究将导致早期发现“处于风险的POAG”个体的方法，测量POAG治疗效率的新方法以及对青光眼病理学机制的新见解。